- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Diatide signs license deal with Angstrom
Radiopharmaceutical firm Diatide last month signed a license agreement with Angstrom Pharmaceuticals that will allow Angstrom to develop cancer-fighting pharmaceuticals. Londonderry, NH-based Diatide will have global exclusive rights to imaging and
Radiopharmaceutical firm Diatide last month signed a license agreement with Angstrom Pharmaceuticals that will allow Angstrom to develop cancer-fighting pharmaceuticals. Londonderry, NH-based Diatide will have global exclusive rights to imaging and therapeutic agents produced from Angstroms tumor-targeting technology. Diatide will pay San Diego-based Angstrom an initial payment, future research and milestone payments, and royalties on product sales, and will provide research support.
Angstrom has developed and patented small cyclic peptides that bind to a key receptor found on the surface of almost all solid tumors, including breast, prostate, colon, and lung. The two firms believe that targeting these receptors with radiotherapeutic agents could obstruct tumor growth.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
